

**PHARMACY AND THERAPEUTICS COMMITTEE
MEDICAID MEETING MINUTES
March 6, 2025**

*Attendance: Microsoft Teams Meeting
Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Connie Chan, Staff/Clinical Pharmacist; Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Sahani de Silva, Pharmacy Student Intern; Dr. Neal Demp, Community Behavior Health; Dawson Do, Pharmacy Student Intern; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Yelena Hedrick, Staff/Clinical Pharmacist; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Demian Elder, Medical Director; Merleen Harris-Williams, Medical Director; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the November 2024 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
<i>Administrative Update</i>	<p><i>2024 Year in Review</i></p> <ul style="list-style-type: none"> <i>• Prior Authorizations</i> <i>• Top 10 Drugs and Drug Classes</i> <i>• NCQA QM/UM 5 Timeliness</i> <i>• Restriction Program</i> 		<i>D. Dolores</i>	<i>Informational</i>

II. Drug Formulary Review/Update


TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Non-PDL Prior Authorization Criteria Review	<p>The Committee reviewed and approved as presented.</p> <ul style="list-style-type: none"> • Neudexta • Palynziq • Rebyota • Sapropterin • Vowst • Rezdiffra 	<p>The Committee approved as presented.</p>	<p>S. Jackson M. Prokopets</p>	<p>Resolved</p>
Quantity Limit Additions	<p>The Committee reviewed the <u>Quantity Limit Additions</u>. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Budesonide 3 mg DR capsule - 3/day • Budesonide 9 mg ER tablet 24h - 1/day • Duloxetine 20 mg capsule - 4/day • Dyanavel XR 2.5 mg/mL suspension - 8 mL/day • ErzoFri 117 mg/0.75 mL - 0.03/day • ErzoFri 156 mg/mL syringe - 0.05/day • ErzoFri 234 mg/1.5 mL syringe - 0.08/day • ErzoFri 351 mg/2.25 mL syringe - 0.081/day • ErzoFri 39 mg/0.25 mL syringe - 0.01/day • ErzoFri 78 mg/0.5 mL syringe - 0.02/day • Gralise ER 300 mg, 450 mg tablet - 1/day • Gralise ER 600 mg, 750 mg, 900 mg tablet - 2/day • Hetlioz LQ 4 mg/mL suspension - 5.27 mL/day • Horizant ER tablet - 2/day • Ibuprofen 100 mg/5mL suspension - 60 mL/day • Jynarque tablet therapy pack - 2/day • Methylphenidate hcl 10 mg/5mL solution - 30 mL/day • Methylphenidate hcl 5 mg/5mL solution - 15 mL/day • Procentra 5 mg/5mL solution - 60 mL/day • Quillichew ER 20 mg, 40 mg tablet - 1.5/day • Quillichew ER 30 mg tablet - 2/day • Quillivant XR 25 mg/5mL suspension - 12 mL/day • Samsca 15 mg tablet - 1/day • Samsca 30 mg tablet - 2/day • Senna 8.6 mg tablet - 8/day • Tolvaptan tablet - 4/day • Xyrem - 18 mL/day • Xywav - 18 mL/day 	<p>The Committee approved as presented. The <u>Quantity Limit Additions</u> will be sent to PARP for approval.</p>	<p>S. Jackson</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Quantity Limit Removals	<p>The Committee reviewed the <i>Quantity Limit Removals</i>. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Calcium 500-vit D3 200 tablet 	<p>The Committee approved as presented. The <i>Quantity Limit Removals</i> will be sent to PARP for approval.</p>	S. Jackson	Resolved
III. Specialty Drug Additions	<p>The Committee reviewed the <i>Specialty Drug Additions</i>. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Alhemo 60mg/1.5mL, 150mg/1.5mL, 300mg/3mL injection • Alyftrek 10-50-125mg, 4-20-50mg tablets • Alyglo 5g/50mL, 10g/100mL, 20g/200mL solution • Attruby 356mg tablets • Bizengri 375mg/18.75mL • Crenessity 25mg, 50mg, 100mg capsules and 50mg/mL solution • Danziten 71mg, 95mg tablet • Datroway 100mg injection • Enhertu 100mg injection • Ensacove 25mg, 100mg capsules • Gomekli capsules and tablet for oral suspension • Imkeldi oral solution • Nemludio 30mg injection • Onapgo 98mg/20mL injection • Opdivo Qvantig • Pemetrexed dipotassium • Revuforj 25mg, 110mg, 160mg tablets • Ryoncil • Steqeyma 45mg/0.5mL, 90mg/mL injection, 130mg/26mL vial • Tevimbra 100mg/10 mL • Tryngolza 80mg injection • Unloxcyt 300mg/5mL vial • Yesintek 45mg/0.5mL, 90mg/mL injection, 45mg/0.5mL, 130mg/26mL vial • Ziihera 300mg powder 	<p>The Committee approved as presented. The <i>Specialty Drug Additions</i> will be sent to PARP for approval.</p>	D. Dolores	Resolved
IV. New Drug Review	<p>R. John presented the <i>New Drug Review</i> list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> • Romvimza (vimseltinib) Capsules • Penmeny (meningococcal groups A, B, C, W, and Y vaccine) Lyophilized Powder for Injection • Vimkunya (chikungunya vaccine, recombinant) Injection • Merilog (insulin aspart-szjj) Injection • Ospomyv (denosumab-dssb) Injection • Xbryk (denosumab-dssb) Injection 	<p>The Committee approved the <i>New Drug Review</i> as presented and recommended.</p>	R. John	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Gomekli (mirdametinib) Capsules and Tablets for Oral Suspension</i> • <i>Emblaveo (avibactam and aztreonam) Lyophilized Powder for Injection</i> • <i>Onapgo (apomorphine hydrochloride) Infusion Device - formerly SPN-830</i> • <i>Journavx (suzetrigine) Tablets - formerly VX-548</i> • <i>Symbravo (meloxicam and rizatriptan) Tablets - formerly AXS-07</i> • <i>Avtozma (tocilizumab-anoh) Injection</i> • <i>Grafapex (treosulfan) Lyophilized Powder for Injection</i> • <i>Datroway (datopotamab deruxtecán-dlnk) Lyophilized Powder for Injection</i> • <i>Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection</i> • <i>Alhemo (concizumab-mtci) Injection</i> • <i>Alyftrek (deutivacaftor, tezacaftor and vanzacaftor)</i> • <i>Tryngolza (olezarsen) Injection</i> • <i>Symvess (acellular tissue engineered vessel-tyod) for Surgical Vascular Implantation</i> • <i>Ryoncil (remestemcel-L-rknd) Cell Suspension for Intravenous Infusion</i> • <i>Ensacove (ensartinib) Capsules</i> • <i>Steqeyma (ustekinumab-stba) Injection</i> • <i>Crenessity (crinecerfont) Capsules and Oral Solution</i> • <i>Unloxcyt (cosibelimab-ipdl) Injection</i> • <i>Bizengri (zenocutuzumab-zbco) Injection</i> • <i>Yesintek (ustekinumab-kfce) Injection</i> • <i>Attruby (acoramidis) Tablets</i> • <i>Imkeldi (imatinib mesylate) Oral Solution</i> • <i>Rapiblyk (landiolol) Lyophilized Powder for Injection</i> • <i>Ziihera (zanidatamab-hrii) Lyophilized Powder for Injection</i> • <i>Revuforj (revumenib) Tablets</i> • <i>Kebilidi (eladocagene exuparvovec-tneq) Suspension for Intraputaminial Infusion – formerly Upstaza</i> • <i>Aucatzyi (obecabtagene autoleucel) Suspension for Intravenous Infusion</i> • <i>Danziten (nilotinib tartrate) Tablets</i> • <i>Emrosi (minocycline hydrochloride) Extended-Release Capsule formerly DFD-29</i> • <i>Orlynvah (sulopenem etzadroxil and probenecid) Tablets</i> 			

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2025.



3/24/2025

Danielle Dolores, Director of Pharmacy Services

Date